A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorNanjing Chia-tai Tianqing Pharmaceutical
About this trial
NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor.
The objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with advanced hematological malignancies.
Eligibility criteria
Qualifiers
≥18 years in age, male or female.
Relapsed/refractory AML patients.
ECOG performance status score is 0 to 2.
Life expectancy of at least 3 months.
Disqualifiers
Receiving anticancer therapy including immunotherapy, targeted therapy, endocrine therapy, radiotherapy and chemotherapy within 2 weeks or 5 half-lives (whichever is longer) prior to starting study treatment.
Receiving any other investigational agents within 4 weeks prior to starting study treatment.
Having major surgery within 4 weeks prior to starting study treatment, or intended to undergo surgery during the trail.
AML with any of the following: 1) acute promyelocytic leukemia; 2) AML with blast crisis of chronic myelogenous leukemia; 3) central nervous system leukemia.
Trial design
Treatments tested in this trial
- NTQ2494 tablet
Treatment groups
72 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov